Beyond oncology - Application of HPMA copolymers in non-cancerous diseases

Xin Ming Liu, Scott C. Miller, Dong Wang

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations


Macromolecular drug conjugates have been developed to improve the efficacy and safety profile of various therapeutic agents for many years. Among them, N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-drug conjugates are the most extensively studied delivery platforms for the effective treatment of cancer. In recent years, the applications of HPMA copolymers for the treatment of a broader range of non-cancerous diseases have also been explored. This review highlights the recent developments in the rational design, synthesis, and evaluation of novel HPMA copolymer-drug conjugates for non-cancerous diseases, such as musculoskeletal diseases, infectious diseases and spinal cord injury. The translation potential of these applications is also briefly discussed.

Original languageEnglish (US)
Pages (from-to)258-271
Number of pages14
JournalAdvanced Drug Delivery Reviews
Issue number2
StatePublished - Feb 17 2010


  • Arthritis
  • Bone-targeting
  • Central nervous system (CNS)
  • HPMA copolymers
  • Infectious diseases
  • Musculoskeletal diseases

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Beyond oncology - Application of HPMA copolymers in non-cancerous diseases'. Together they form a unique fingerprint.

Cite this